NCT03686124: TCR-engineered T Cells in Solid Tumors

NCT03686124
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PRAME
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient’s tumor must express PRAME
Exclusions: Patients with active brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03686124

Comments are closed.

Up ↑